BBIO   $25.16  -3.31% Market Closed After Close 25.07 -0.36%

BridgeBio Pharma Inc
Last Events:

2023-08-09 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-06 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-08-05 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-05 Signal in RSI changed from bearish reversal to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bullish weakening to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: entrance to the overbought zone.

2023-08-03 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: entrance to the overbought zone.


Current temperature: 5.43
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 48.00
Mean unverified/preliminary 48.00 / 48.00
Target Price Low / High 37.00 / 70.00
Median / STD DEV 46.00 / 8.05
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi ActivelyBuy Sell Sell
macd None None None
stoch None None None
ma20 ActivelyBuy None Sell
ma50 None None None
ma100 None Sell Sell
Candlestick PatternOct. 18, 2024 Bearish Three Inside Down - pattern is a made up of three candlesticks. Big white candlestick appears on the first day in a uptrend. The second day body is engulfed by the body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.
ISIN US10806X1028
ceo Dr. Neil Kumar Ph.D.
Website https://bridgebio.com
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.